Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

MDR summary reporting expansion planned by FDA; program begins with about 30 firms.

This article was originally published in The Gray Sheet

Executive Summary

SUMMARY MDR REPORTING PROGRAM TO BEGIN WITH 30 MANUFACTURERS that responded to FDA's request for participants mailed out July 31. Under the reporting schedule outlined in the agency's letter to firms, the first quarterly reports will be due in Jan. 31, 1998. FDA is in the process of sending letters of acceptance to the 30 companies participating in summary reporting. The letters note that the firms are exempt from regular MDR reporting requirements for events covered by summary reporting. FDA has identified types of events for the devices that qualify for summary reporting. Manufacturers also can propose additional types of events, but they would have to be reviewed by FDA.

Latest Headlines
See All
UsernamePublicRestriction

Register

MT008862

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel